Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T4258 |
TLR7 agonist 2
TLR7-agonist-1,TLR7-IN-1 |
TLR | Immunology/Inflammation |
TLR7 agonist 2 (TLR7-IN-1) 是选择性 Toll 样受体 7 激动剂,LEC 值为 0.4 μM。 | |||
T38614 |
TLR7 agonist 3
|
||
TLR7 agonist 3 (Compound 2), a potent activator of toll-like receptor 7 (TLR7), plays a critical role in initiating immune responses, positioning it as a promising target for immunomodulator development. | |||
T61260 |
Ruzotolimod
|
||
Ruzotolimod, an agonist of TLR7, exhibits promising potential for investigating HBV, COVID-19, and SARS-CoV-2 infections (WO2021130195A1)[1]. | |||
T75213 | TLR7 agonist 12 | ||
TLR7 agonist12 (example 20) 是一种针对惰性淋巴系统恶性肿瘤具有广泛抗肿瘤活性的TLR7激动剂及嘌呤核苷类似物。其抗癌机制主要通过抑制DNA合成和诱导细胞凋亡(apoptosis)来实现。 | |||
T40040 | TLR8 agonist 2 hydrochloride | ||
TLR8 agonist 2 hydrochloride is a highly potent and selective agonist for human TLR8, exhibiting an EC50 of 3 nM. However, its activity towards human TLR7 is considerably weaker, with an EC50 of 33.33 μM. | |||
T61601 | TLR7/8 antagonist 2 | ||
TLR7/8 antagonist 2 (Compound 15) is a highly potent and orally active agonist of TLR7/8, exhibiting IC50 values of 4.9 and 0.6 nM for TLR7 and TLR8, respectively. Its strong affinity for these receptors makes it a promising candidate for the treatment and investigation of autoimmune diseases, including lupus erythematosus, which is associated with inappropriate activation of TLR7 and TLR8. Consequently, TLR7/8 antagonist 2 represents a valuable tool for research in the field of autoimmune disea... | |||
T40039 |
TLR8 agonist 2
TLR8 agonist 2 |
||
TLR8 agonist 2 is a highly effective and specific compound that activates TLR8, possessing an EC 50 of 3 nM in human TLR8. Notably, TLR8 agonist 2 demonstrates lower activity towards human TLR7, with an EC 50 of 33.33 μM. | |||
T61110 | UC-1V150 | ||
UC-1V150 is a distinct TLR7 agonist, which activates cellular immune responses and exhibits anti-tumor effects. It also serves as a precursor for the synthesis of ISAC molecules, known as immune-stimulating antibody conjugates [1] [2]. | |||
T14035 |
3M-011
|
TLR | Immunology/Inflammation |
3M-011, a potent dual toll-like receptor TLR7/8 agonist and cytokine inducer, serves as a powerful adjuvant to radiotherapy, eliciting significant local and systemic immune responses. Additionally, it effectively inhibits H3N2 influenza viral replication in the nasal cavity and exhibits strong antitumor activity[1][2][3]. | |||
T5499 |
gardiquimod TFA salt
|
||
Gardiquimod diTFA,咪唑啉类似物TLR7/8激动剂,可特异性抑制巨噬细胞和活化外周血单个核细胞(PBMCs)的HIV-1感染。在浓度低于10 μM时,该化合物特异性激活TLR7。 | |||
T60517 | CL097 hydrochloride | ||
CL097 hydrochloride 是一种有效的 TLR7和 TLR8激动剂。CL097 hydrochloride 可在巨噬细胞中诱导促炎细胞因子和 NADPH 氧化酶启动活性,从而增加 fMLF 刺激的ROS 产生。 | |||
T22091 |
Imiquimod hydrochloride
|
||
Imiquimod hydrochloride (R 837 hydrochloride)是一种免疫反应调节剂,是一种选择性的 toll 样受体 7 (TLR7) 激动剂。Imiquimod hydrochloride 在体内表现出抗病毒和抗肿瘤作用。Imiquimod hydrochloride 可用于外生殖器、肛周疣、癌症和 COVID-19 的研究。 | |||
T83895 |
NCI 126224
NSC 126224 |
||
NCI 126224 是一种 toll-like receptor 4 (TLR4) 的拮抗剂。它在 RAW 264.7 巨噬细胞中,选择性抑制由 TLR4 激动剂 LPS 引起的一氧化氮 (NO) 产生(IC50 = 0.31 µM),而对 TLR7/8 激动剂 R-848、TLR1/2 激动剂 Pam3CSK4 以及 TLR3 激动剂 poly(I:C) 的影响较小;但对于相同细胞中由 TLR2/6 激动剂 FSL-1 引起的 NO 产生,其抑制作用在 0.6 µM 时亦显现。此外,NCI 126224 在 BV-2 微胶质细胞的报告实验中抑制了 LPS 引起的 NF-κB 活性,并在 RAW 264.7 巨噬细胞中降低了 LPS 引起的 IL-1β 和 TNF-α 水平(IC50s = 5.92, 0.42, 和 1.54 µM,分别)。 |